- Home
- PSNL vs AGIO Comparison
PSNL vs AGIO Comparison
Compare PSNL & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | AGIO |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PSNL | AGIO |
|---|---|---|
| Price | $15.65 | $31.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $15.17 | ★ $46.00 |
| AVG Volume (30 Days) | ★ 2.1M | 932.2K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,648,000.00 | $43,011,000.00 |
| Revenue This Year | $21.10 | $229.47 |
| Revenue Next Year | $30.66 | $94.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.96 | $22.24 |
| 52 Week High | $18.89 | $46.00 |
Technical Indicators
Market Signals| Indicator | PSNL | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.41 | 45.01 |
| Support Level | $13.68 | $26.74 |
| Resistance Level | $16.58 | $35.77 |
| Average True Range (ATR) | 0.35 | 1.07 |
| MACD | -0.09 | -0.03 |
| Stochastic Oscillator | 10.70 | 43.12 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.